Operates a network of companion animal cancer treatment centers in the United States. Develops and implements bone marrow transplantation procedures for pets. Now — the numbers.
An investor who bought at the very peak is down 80% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
We do not hold enough financial data on this company to point to a strength.
The stock sits at $0.0001. Under exchange rules, stocks that stay below $1 for too long risk being removed from the market.
No score published: we hold no usable price for this ticker, and a grade beside a missing price says nothing.
One-line summary: few numbers, an untested story. Keep watching.
Not covered, because the filings we hold do not carry it: revenue and profit, the growth trend, the balance sheet, earnings execution, the revenue breakdown.